Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (5R01CA248919-02, F30 CA247262, R01CA190700, R01CA248919)
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (1R21AI163421-01A1, 1R01AI162643-01A1, 5R01AI150297-04, 1R21AI164142-01A1, 5R01AI150297, R21AI164142)
Received: 21 December 2021
Accepted: 7 September 2022
First Online: 21 October 2022
: R.D.S. is a co-founder, paid consultant and stockholder of Jounce Therapeutics and Asher Biotherapeutics and paid consultant and stockholder of A2 Biotherapeutics, Arch Oncology, Asher Biotherapeutics, Codiak Biosciences, NGM Biotherapeutics, Meryx and Sensei Biotherapeutics. K.M.M. is a paid member of the scientific advisory board of Harbour BioMed. The other authors declare no competing interests.